Financings in Brief: Boston Biomedica
This article was originally published in The Gray Sheet
Executive Summary
Boston Biomedica: Files registration statement with the Securities and Exchange Commission for an initial public offering with a proposed aggregate value of $22.1 mil. The manufacturer of quality control products for in vitro diagnostics plans to use $3.6 mil. of proceeds from the offering to repay debt; $1 mil. will fund an expansion of the firm's West Bridgewater, Massachusetts facilities. Remaining proceeds will be used for "general corporate purposes, including working capital, as well as for potential acquisitions and alliances," the registration statement says. Oscar Gruss & Son Incorporated and Kaufman Bros., L.P. are underwriting....
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.